$40,000 of AMYLYX PHARMACEUTICALS lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"rare disease and access to innovation rare disease and access to innovation"
You can find more data on corporate lobbying on Quiver Quantitative.
AMLX Insider Trading Activity
AMLX insiders have traded $AMLX stock on the open market 10 times in the past 6 months. Of those trades, 1 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $AMLX stock by insiders over the last 6 months:
- GINA MAZZARIELLO (Chief Legal Officer) has made 0 purchases and 4 sales selling 36,867 shares for an estimated $637,735.
- JUSTIN B. KLEE (Co-Chief Executive Officer) has made 0 purchases and 2 sales selling 17,495 shares for an estimated $255,318.
- JOSHUA B COHEN (Co-Chief Executive Officer) has made 0 purchases and 2 sales selling 17,474 shares for an estimated $254,891.
- JAMES M FRATES (Chief Financial Officer) sold 3,557 shares for an estimated $52,096
- KAREN FIRESTONE purchased 3,800 shares for an estimated $51,338
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
AMLX Hedge Fund Activity
We have seen 74 institutional investors add shares of AMLX stock to their portfolio, and 75 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 3,256,064 shares (-47.8%) from their portfolio in Q1 2026, for an estimated $45,259,289
- SIREN, L.L.C. added 1,230,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $17,097,000
- FRANKLIN RESOURCES INC added 1,061,473 shares (+88.4%) to their portfolio in Q1 2026, for an estimated $14,754,474
- BARCLAYS PLC added 676,677 shares (+229.2%) to their portfolio in Q1 2026, for an estimated $9,405,810
- JUPITER ASSET MANAGEMENT LTD added 577,080 shares (+3705.4%) to their portfolio in Q1 2026, for an estimated $8,021,412
- SOFINNOVA INVESTMENTS, INC. removed 527,099 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $7,326,676
- SILVERARC CAPITAL MANAGEMENT, LLC removed 506,242 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $7,036,763
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AMLX Analyst Ratings
Wall Street analysts have issued reports on $AMLX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 03/03/2026
To track analyst ratings and price targets for AMLX, check out Quiver Quantitative's $AMLX forecast page.
AMLX Price Targets
Multiple analysts have issued price targets for $AMLX recently. We have seen 5 analysts offer price targets for $AMLX in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Seamus Fernandez from Guggenheim set a target price of $40.0 on 06/25/2026
- Graig Suvannavejh from Mizuho set a target price of $21.0 on 04/28/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $34.0 on 03/25/2026
- James Condulis from Stifel set a target price of $21.0 on 03/03/2026
- Geoff Meacham from B of A Securities set a target price of $19.0 on 02/20/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
